Clinical Trial Update: Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period [Phase 3]

View source ↗

Summary

Phase 3 trial investigating vildagliptin for prevention of diabetes after renal transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes
• Disorder Related to Renal Transplantation

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Disorder Related to Renal Transplantation, Diabetes | Phase 3 | Status: UNKNOWN